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Macaqueogenicity and efﬁcacy of a bimodal prime/boost vaccine regimen given by various
routes in the Simian immunodeﬁciency virus (SIV) rhesus monkey model for AIDS. Twelve animals were
immunized with SIV DNA-vectors followed by the application of a recombinant adenovirus (rAd5) expressing
the same genes either intramuscularly (i.m.) or byoropharyngeal spray. The second rAd5-applicationwas given
i.m. All vaccinees plus six controls were challenged orally with SIVmac239 12 weeks post-ﬁnal immunization.
Both immunization strategies induced strong SIV Gag-speciﬁc IFN-γ and T-cell proliferation responses and
mediated a conservation of CD4+ memory T-cells and a reduction of viral load during peak viremia following
infection. Interestingly, the mucosal groupwas superior to the systemic group regarding breadth and strength
of SIV-speciﬁc T-cell responses and exhibited lower vector speciﬁc immune responses. Therefore, our data
warrant the inclusion of mucosal vector application in a vaccination regimenwhich makes it less invasive and
easier to apply.
© 2008 Elsevier Inc. All rights reserved.IntroductionInducing a broad, durable and protective immunity is the primary
aim of any AIDS vaccine. A wide range of vaccine vectors and delivery
strategies have been tested in pre-clinical studies using simian immu-
nodeﬁciency virus (SIV)-infected monkeys (Casimiro et al., 2004;
Doria-Rose et al., 2003) or mice (McGettigan et al., 2006, 2001). The
monkeymodel is themost relevant for such studies because it provides
an opportunity to test both protective vaccine candidates (reviewed in
McMichael, 2006) and chemo-prophylactic regimens (Van Rompay et
al., 2006). Despite suggested caution particularly in the light of the
failed human STEPHIV-1Merck vaccine trial (Sekaly, 2008), adenoviral
vectors generated highly potent and broad immune responses
(Malkevitch et al., 2006, 2003). Of these, replication defective human
adenovirus serotype 5 (rAd5) vectors expressing SIV proteins are
frequently employed since they elicit a strong immune responsestahlh@dpz.eu
rk and are listed in alphabetical
l rights reserved.against the product of the gene incorporated (Shiver et al., 2002). Pre-
existing immunity to adenoviral vectorsmay negate its overall efﬁcacy
(Kostense et al., 2004; Sumida et al., 2005; Thorner et al., 2006), and is
to blame in part for the failure of the clinical vaccine trial involving
rAd5-vectors (Sekaly, 2008). However, these deﬁciencies can be
overcome, including heterologous prime-boost regimes (Casimiro et
al., 2003, 2004, 2005; Thorner et al., 2006). Using a similar vector
design, we previously demonstrated strong anamnestic SIV-speciﬁc
interferon (IFN)-γ responses capable to signiﬁcantly limit viremia in
vaccinated macaques after challenge (Suh et al., 2006). One critical
aspect in the design of an effective vaccine is the development of a
memory T-cell response. Recent studies in the SIVmonkeymodel have
shown that T-cell memory consists of distinct populations of central
and effector memory cells (Pitcher et al., 2002). Here we deﬁned the
central memory T-cells as CD4+95+29+28+, thereby combining two
previous deﬁnitions of memory T-cell markers (Picker et al., 2006;
Sopper et al., 1997).
Interleukin-15 (IL-15) is a pleiotropic cytokinewhich has been used
in vaccination and therapeutic studies with ambivalent results (Boyer
et al., 2007; Demberg et al., 2008; Halwani et al., 2008; Hryniewicz et
al., 2007; Mueller et al., 2008). Given after SIV-infection IL-15 expands
both the CD4+ and CD8+ effector memory T-cell compartments (Picker
et al., 2006) but it is also known to be a potent regulator of B- and
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cellular immune response IL-15 was included in our DNA prime rAd5
booster regimen. In addition, the DNA prime was supplemented by a
synthetic immunostimulatory peptidewhich attracts human dendritic
cells (Yang et al., 2002) and selectively enhances vaccine induced CD8+
T-cell responses in mice (Lee et al., 2005).
Compared to the human STEP study regimen (Sekaly, 2008), our
vaccine approach using the macaque model for AIDS, was completely
different. First, we utilized E1 and E3 deleted rAd5, while only E1-
deleted rAd5 was used in the STEP study. Second, we applied a
heterologous prime-boost regimen comprisingmultigenic DNA-prime
and recombinant rAd5 boost. We modiﬁed our previous regimen
(Stahl-Hennig et al., 2007b) by using codon-optimized SIV DNA plus
human IL-15 DNA followed by boosting with recombinant rAd5
expressing the same SIV genes as well as IL-15. Third, in contrast to
the STEP study, we focused on the impact of mucosal immunization on
vaccine efﬁcacy. One study arm combined both mucosal and systemic
administration of the rAd5 vaccine and was compared to a group
receiving the vaccines systemically only. Following an oral challenge
with SIVmac239 both vaccine groups revealed substantial protection
as demonstrated by lower levels of peak viremia and better conserva-
tion of the central memory T-cell population compared to control
animals. Furthermore, a combination of mucosal and systemic rAd5
immunization was more immunogenic than rAd5 given systemically
alone in DNA vaccine-primed macaques.
Results
Strongest SIV-speciﬁc T-cell proliferation and Gag-speciﬁc IFN-γ ELISpot
responses in the mucosal vaccine group
T-cell proliferation responses in blood were determined in all
animals on the day of immunization and every 2 or 4weeks, starting at
8weeks after the ﬁrst immunization. Proliferative activitywasweak or
undetectable either after DNA priming alone (data not shown) or after
the ﬁrst booster immunization with rAd5. Only after the second
booster immunizationwewere able todemonstrate risingproliferative
responses in the mucosal group by week 40 (Fig. 1A). On the day of
challenge at week 44, these responses developed strongly in the
mucosal group (mean SI=11.5) compared to the systemic group (meanFig. 1. T-cell proliferation responses against whole inactivated SIV (A) and SIVgag-
speciﬁc IFN-γ ELISpot response proﬁles (B) during immunization and after challenge.
The arrows indicate the rAd5 immunizations and day of challenge. The asterisk depicts a
statistical difference (pb0.05) between the vaccine groups.SI=4.5; p=0.041). Two weeks after challenge, T-cell proliferation
responses dropped in all vaccinees, reappearing 2weeks later although
these could not be sustained thereafter.
Strongest SIV Gag-speciﬁc IFN-γ ELISpot responses in the mucosal group
on the day of challenge
SIV Gag IFN-γ ELISpot responses peaked in the systemic group
2weeks after ﬁrst rAd5-boost (Fig. 1B, week 26) andwere signiﬁcantly
higher than those in the mucosal group (p=0.009). For the mucosal
group these responses only peaked after the second rAd5-adminis-
tration given i.m. while no signiﬁcant responses were detected after
the ﬁrst boosting given mucosally in this group. Cumulative ELISpot
responses against all peptides analyzed were relatively uniform for
animals within the systemic and mucosal groups after the second
boost (Fig. 2A) and remained so even for the relatively strong Gag-
responses. Comparing means of all and Gag alone ELISPOT responses
for each group revealed no signiﬁcant difference between the two
vaccine groups 2 weeks after the second boost (Fig. 2C). On the day of
challenge these IFN-γ responses had declined in both groups but were
signiﬁcantly higher in themucosal than in the systemic group (Fig. 2D).
Our results also revealed that the mucosal group reacted against a
wider spectrum of different SIV-peptide pools at challenge compared
to the systemic group (Fig. 2B). After challenge, SIV Gag INF-γ ELISpot
levels were signiﬁcantly higher for vaccinees than control animals at
4 wpc but were not signiﬁcantly different between the two vaccine
groups. Moreover, these ELISPOT values remained higher in the
mucosal than in the systemic group during the whole post-infection
phase (Fig. 1B).
Collectively, these observations suggest a higher and more diverse
immune response in the mucosal group.
Higher SIV-speciﬁc IgG binding and neutralizing responses in the
mucosal group contrasting limited serum IgA in both groups
Animals of the mucosal group receiving the rAd5-boost ﬁrst orally
and then systemically developed higher SIV Gag p27 and envelope
gp130 binding-antibody responses on the day of challenge when
compared to the group boosted twice systemically. However, these
differences were not signiﬁcant between the vaccine groups (data not
shown).
SIVmac251 neutralizing antibody (nAb) titers appeared in the sys-
temic group 4 weeks after the ﬁrst rAd5 vaccination (Fig. 3A) whereas
in the mucosal group nAb titers were not present after oral immu-
nization, but observed only after systemic boosting. Interestingly, on
the day of challenge the mean nAb titer was signiﬁcantly higher in the
mucosal than in the systemic group. In contrast, neutralization
antibodies against SIVmac239, which is more resistant to neutraliza-
tion than SIVmac251, were undetectable during the immunization
period. As a measure of mucosal immune responses, we examined the
presence of SIV Env- and Gag-speciﬁc IgA in plasma by means of an
ELISA assay. During immunization IgA antibodies against SIV gp130
and SIV capsid protein were transiently detectable at low titers in all
animals from the mucosal group and in ﬁve of six monkeys from the
systemic group (Table 1). Following challenge all vaccinees showed a
rapid surge in their SIV IgA antibodies by week 2 which was signi-
ﬁcantly higher in the mucosal group compared to the systemic one
(pb0.05). In rectal swabs we did not detect SIV-speciﬁc IgA (data not
shown). Either these responseswere not induced at all or their absence
could have been due to technical problems concerning sample storage.
Adenovirus neutralization transiently affected SIV-speciﬁc T-cell
proliferation
Neutralizing antibody titers against adenovirus (nAbrAd5) were
measured by a green ﬂuorescent foci reduction assay. They were
Fig. 2. Individual cumulative IFN-γ ELISpot responses against different SIV peptide pools in the two vaccine groups at week 36 (4 weeks after ﬁnal immunization) (A) and at week 44
(day of challenge) (B) and the mean of the total and the Gag ELISpot responses for each group at week 36 (C) and at week 44 (D) are shown. The Gag- and the total ELISpot responses
were signiﬁcantly higher in the mucosal group on the day of challenge but not at 4 weeks after ﬁnal immunization. Systemic, vaccine group systemically immunized; mucosal,
vaccine group where systemic and mucosal vaccine application were combined; A⁎01 indicates the Mamu-A⁎01, B⁎17 the Mamu-B⁎17 animals.⁎, p-valueb0.05; ⁎⁎, p-valueb0.01.
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the systemic group; while no titers were scored in the mucosal
group after oral rAd5 application (Fig. 3B). Four weeks after the
second rAd5 application, peak nAbrAd5 titers were reached in the
systemic group, and these were signiﬁcantly higher than those inFig. 3. Geometric means of neutralizing antibodies against SIVmac251/32H during
immunization and after challengemeasured by sMAGI-assay (A) and against adenovirus
measured in a green ﬂuorescent foci reduction assay (B). Values are shown as
reciprocals of serum dilution yielding N80% (SIV) and N50% (adenovirus) reduction,
respectively of focus forming units. ⁎, signiﬁcant (pb0.05) and ⁎⁎ highly signiﬁcant
(pb0. 01) differences between the systemic group compared to the mucosal group. The
arrows indicate the immunizations and day of challenge.the mucosal group. The difference in vector-speciﬁc immunity
between the two vaccine groups had dissipated by the time of
challenge.
Nextwe investigatedwhether these nAbrAd5 titers had any impact
on the SIV-speciﬁc immune responses. Correlation analysis showed
that the pre-challenge nAbrAd5 titers did not signiﬁcantly negate
subsequent pre- or post-challenge INF-γ ELISpot or antibody
responses as obvious by the lack of signiﬁcant association. However,
4 weeks after the second rAd5 immunization, the point in time with
the largest difference in nAbrAd5 titers between the groups with
respect to vaccine–vector neutralization, the increased levels of
nAbrAd5 titers were associated with suppressed T-cell proliferation
appearing 4 weeks later at week 40 (p=0.004).
Reduced plasma viral RNA load during acute infection and its association
with SIV-neutralizing antibodies
Although the oral mucosa is not considered to be major viral entry
sites in heterosexual HIV transmission, we performed an oral chal-
lenge. This mucosal route is very reliable compared to experimental
rectal infection (own unpublished data, Koopman et al. 2004), truly
atraumatic (Stahl-Hennig et al. 1999) and a single exposure requires
less infectious units (6000 TCID50) compared to vaginal infection (105
TCID50; Miller et al. 2005).
After oral SIVmac239 challenge at week 44, plasma viral load was
quantiﬁed by real time PCR. Plasma viremia is reported as geometric
means for each group (Fig. 4A). All animals became productively
infected at 2 wpc (Figs. 4B–D). However, vaccinated macaques
demonstrated signiﬁcant control of acute viremia 2 and 4 wpc
(p=0.002) independent of the route of immunization. This reduction
in viremia was maintained only shortly after the acute phase, and did
not last beyond 12 to16 wpc (Fig. 4A). The lack of signiﬁcant differ-
Table 1
SIVgp130 and -p27 speciﬁc IgA-titer in serum of vaccinees during immunization and after challenge
wpi/wpc Mucosal group Systemic group
2118 2151 2161 2168 2180 10425 2107 2121 2141 2145 2153 2169
SIVgp130
24 5 10 b5 b5 b5 b5 b5 b5 b5 b5 b5 10
32 5 5 b5 b5 b5 5 b5 b5 5 b5 b5 10
34 80 80 5 b5 40 10 10 10 20 b5 10 40
44/0 20 10 b5 5 5 b5 b5 b5 5 b5 b5 40
46/2 80 160 160 80 320 80 20 80 40 20 10 160
48/4 160 160 80 160 80 40 10 80 40 40 40 160
SIVp27
24 10 5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5
32 20 b5 b5 10 b5 b5 b5 b5 5 b5 b5 10
34 40 5 5 5 5 b5 5 10 20 b5 5 40
44/0 5 b5 b5 20 10 5 5 b5 5 b5 b5 20
46/2 40 80 160 320 320 320 160 80 640 80 20 640
48/4 40 80 160 160 160 160 160 160 320 20 20 1280
wpi: weeks after ﬁrst immunization; wpc: weeks after challenge.
The four- or ﬁve-digit numbers are macaque designations.
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by the early death of two rapid progressors in the control group (Fig.
4B and Table 2).
In order to assess the impact of neutralizing SIV antibodies on
viremia, thesewere correlatedwith plasma viral load. The titer of nAbs
at 2 wpc correlated inversely with the RNA load at 2 and 4 wpc
(p≤0.03) indicating a role of nAb responses to SIV in control of viral
replication during acute infection.
Better conservation of CD4+ memory cells in vaccinees after challenge
As a measure of vaccine efﬁcacy and to follow the clinical and im-
munological progress of the animals, T-cells were analyzed by
multicolor ﬂow cytometry at regular intervals. To monitor changes in
memory cells in the different study arms, T-cell memory subsets were
measured and normalized to pre-infection values. We considered the
analysis of CD4+195+ T-cells to be important since these are usually the
ﬁrst targets of SIV-infection (Mattapallil et al., 2005). This population
was signiﬁcantly conserved in the vaccinees within the ﬁrst 4 weeks
after infection while it was largely reduced in the controls (data not
shown). CD4+ central-memory cells (TCM) deﬁned as CD4+29+95+28+
T-cells, were signiﬁcantly reduced in control animals compared to
vaccinees during the acute phase at 2 wpc (Fig. 5). Additional analyses
of CD8+ memory T-cells revealed a strong and short-lived increase of
central-memory subsets at 2wpc in the vaccinees. By contrast, only the
proportion of effector-memory cells (TEM) increased in controls at this
time point. We observed no differences in the naïve T-cell subset
between control animals and vaccinees (data not shown).
Preservation of CD4+ memory T-cells correlated with SIV speciﬁc T- and
B-cell responses and viral load
Because of the pronounced differences in the degree of TCM pre-
servation at 2 wpc, we used this point in time to compute correlation
statistics. The proliferation responses occurring 4 weeks after second
Ad5 immunization until 2 weeks after challenge were found to con-
sistently correlate positively with TCM values. Moreover, the propor-
tion of these cells during the acute infection phase inversely correlated
with the plasma viral RNA load from 2 to 20 weeks post-challenge
(pb0.03), coincidingwith signiﬁcantly lower viral loads in bothvaccine
groups. The proportions of these TCM cells also correlated with higher
titers of SIV binding antibodies to p27 and gp130 during the acute and
post-acute phase of infection (pb0.04). These data indicate a strong
anamnestic immune response linked toT-helper cells, particularly due
to conserved TCM.Mhc class I genotypes control latent but not acute viremia
Rhesus macaques wereMhc-typed to assign those carrying similar
Mhc-class I genotypes evenly to the three experimental groups (Table
2). We had demonstrated earlier that vaccinees controlled acute vire-
mia better than control animals (Figs. 4A–D). Remarkably, this viremia
control between vaccinees and control animals at 2 wpc was still
evident even after excluding those immunized macaques that were
positive for the Mamu-A⁎01 allele in our analyses (p=0.004) and
remained so until 8 wpc (pb0.05) (data not shown). Moreover, there
was no difference in viremia control betweenMamu-A⁎01 positive and
negative vaccinated animals during the acute phase of infection (Fig.
4E). During this period, the genetic background did not seem to exert
direct inﬂuence on acute viremia control. But at later time-points
starting 12 wpc, Mamu-A⁎01 positive vaccinees controlled viral repli-
cationmore efﬁciently than the other immunizedmacaques that were
Mamu-A⁎01 negative (pb0.04, Fig. 4E). To allow for a more detailed
assessment of the effects of vaccination, four Mhc-identical half-sibs
positive forMamu-A1⁎01 and -B⁎17were included in this study; two of
them being immunized, the other two serving as controls. All of them
became elite controllers after SIV infection. Although a statistical
analysis is not possible with these small numbers, there is a trend that
the two immunized macaques reduced peak viremia and were able to
control viral replication below detection limits earlier than the two
non-vaccinated macaques (Fig. 4F). Of two Mhc-identical half-sibs
displaying rapid disease progression, the mucosally immunized
macaque 2180 survived nearly twice as long as the non-immunized
macaque 2175 (27 vs. 14 wpc, Table 2). Thus, in these macaques a
positive effect of the vaccination was evident.
For further comparison four Mhc-similar macaques carrying a
genotype associated with slow disease progression (Sauermann et al.,
2008) were included. Again statistical analysis was not possible due to
small group sizes, but compared to the non-vaccinated macaques
(2165 and 2194), the two immunized ones (2168 and 2169) had a
reduced viral load at peak viremia. The individual viral set point of
these four animals was reached after 24 weeks of infection (Fig. 4G).
Unfortunately, one immunized macaque (2169) had to be euthanized
after 27 wpc due to an SIV-unrelated disease (Table 2). The other ma-
caque (2168) that was immunized mucosally survived longer than the
two control macaques.
To compare the effects of immunization, two other Mhc-similar
macaques, 2161 and 2145 carrying the Mhc-alleles Mamu-B⁎65 and
-B⁎6901 were included in the vaccine groups. The mucosally immu-
nizedmacaque 2161 also outlasted the systemically immunized animal
2145 for 6 months (Table 2). However, Kaplan–Meier analysis on sur-
Fig. 4. Viral loads in vaccinated and control animals and inﬂuence of Mhc class 1 allele on viremia control after oral challenge with SIVmac239. RNA viral loads expressed as RNA
equivalents per milliliter plasma are shown as geometric mean of each group (A), for the individual animals per group (B–D), forMamu-A⁎01 positive, respectively negative vaccinees
(E), for Mamu-A⁎01/B⁎17 Mhc identical animals (F) and for the four Mhc-identical siblings (G). ⁎⁎, p-valueb0.01; †, death; °, indicates the Mamu-A⁎01animals.
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signiﬁcance.
In conclusion, the combined data of the different experimental
groups as well as the single observations of Mhc-identical macaques
show that the signiﬁcant reduction in acute viremia was induced by
vaccination and that genetic background played a major role late after
resolution of acute infection. In addition, including mucosal immuni-
zation appeared to prolong the survival time in our study animals
(Table 2).
Discussion
In pre-clinical AIDS vaccine studies utilizing the non-human pri-
mate model DNA prime–viral vector booster immunization strate-gies in which vaccines were given systemically have been widely
pursued (Casimiro et al., 2005; De Rose et al., 2007; Hanke et al.,
1999; Hel et al., 2002; Letvin et al., 2006; Makitalo et al., 2004;
Mattapallil et al., 2005; Shiver et al., 2002; Stolte-Leeb et al., 2008;
Suh et al., 2006).
In our study we applied different immunization routes using a SIV-
DNA/recombinant adenovirus prime boost regimen to investigate both
humoral and T-cell immune responses and to analyze for efﬁcacy. We
demonstrated in DNA vaccine-primed rhesus macaques that consecu-
tive oral and systemic booster immunizations with rAd5 induced a
strongerGag-speciﬁc T-cell, lymphoproliferative aswell as binding and
neutralization antibody response against SIV than two corresponding
systemic immunizations. However, therewere no differences between
the vaccine groups in vaccine-induced SIV-speciﬁc IgA responses, the
Table 2
Mhc class I alleles of the experimental macaques
Animala MhcMamu-
A-alleles
MhcMamu-B-alleles Survival (weeks
post-challenge)
Sham vaccinated macaques
2139b A1⁎01, A2⁎05 B⁎17, B⁎29 Alive 112
A1⁎08, A3⁎1303,
A2⁎05
B⁎21, B⁎28, B⁎45
2155b A1⁎01, A2⁎05 B⁎17, B⁎29 Alive 112
A1⁎08, A3⁎1303,
A2⁎05
B⁎21, B⁎28, B⁎45
2171 A1⁎04, A4⁎1403 B⁎12, B⁎22, B⁎3001,
B⁎46, B⁎49, B⁎57
25
2165c A1⁎08, A3⁎1303,
A2⁎05
B⁎38, B⁎46, B⁎4701 102
A1⁎04, A4⁎1403 B⁎12, B⁎22, B⁎3001,
B⁎46, B⁎49, B⁎57
2175d,e A1⁎11, A2⁎05 B⁎48 14
A1⁎04, A4⁎1403 B⁎12, B⁎22, B⁎3001,
B⁎46, B⁎49, B⁎57
2194c A1⁎08, A3⁎1303,
A2⁎05
B⁎38, B⁎46, B⁎4701 110
A1⁎04, A4⁎1403 B⁎12, B⁎22, B⁎3001,
B⁎46, B⁎49, B⁎57
Systemic group
2107 A1⁎01, A2⁎05 B⁎22, B⁎12 Alive 112
A1⁎08, A3⁎1303,
A2⁎05
B⁎26, B⁎27, B⁎3003,
B⁎43, B⁎49, B⁎57
2121 A2⁎05, A4⁎1403 B⁎17, B⁎2901 48
A1⁎02, A3⁎1302 B⁎01, B⁎07, B⁎3002, B⁎57
2141d A1⁎04, A4⁎1403 B⁎38, B⁎48, B⁎41 Alive 112
A1⁎08, A3⁎1303,
A2⁎05
B⁎21, B⁎28, B⁎45
2145 A1⁎08, A3⁎1303,
A2⁎05
B⁎65, B⁎6901, B⁎46 77
A1⁎08, A3⁎1303,
A2⁎05
B⁎21, B⁎28, B⁎45
2153b A1⁎01, A2⁎05 B⁎17, B⁎29 Alive 112
A1⁎08, A3⁎1303,
A2⁎05
B⁎21, B⁎28, B⁎45
2169c A1⁎08, A3⁎1303,
A2⁎05
B⁎38, B⁎46, B⁎4701 27
A1⁎04, A4⁎1403 B⁎12, B⁎22, B⁎3001,
B⁎46, B⁎49, B⁎57
Mucosal group
2118d A1⁎01, A2⁎05 B⁎22, B⁎12 Alive 112
A1⁎02, A3⁎1302 B⁎01, B⁎07, B⁎3002, B⁎57
2151b A1⁎01, A2⁎05 B⁎17, B⁎29 Alive 112
A1⁎08, A3⁎1303,
A2⁎05
B⁎21, B⁎28, B⁎45
2161 A1⁎04, A4⁎1403 B⁎65, B⁎6901, B⁎46 101
B⁎38, B⁎12, B⁎3001,
B⁎46, B⁎49, B⁎57
2168c A1⁎08, A3⁎1303,
A2⁎05
B⁎38, B⁎46, B⁎4701 Alive 112
A1⁎04, A4⁎1403 B⁎12, B⁎22, B⁎3001,
B⁎46, B⁎49, B⁎57
2180d,e A1⁎11, A2⁎05 B⁎48 27
A1⁎04, A4⁎1403 B⁎12, B⁎22, B⁎3001,
B⁎49, B⁎57
10425d A1⁎04, A4⁎1403 B⁎69, B⁎48, B⁎41 Alive 112
a The four or ﬁve-digit numbers are macaque designations.
b The macaques represent Mhc-identical siblings.
c The macaques have identical Mhc class 1 alleles.
d The macaque carries moreMhc class 1 genes judged by the DNA-sequences from its
parents.
e The macaques represent Mhc-identical siblings.
Fig. 5. Proportion of central-memory T-cells (TCM) in vaccinated and control animals
after oral challenge with SIVmac239. TCM were deﬁned as CD4+29+95+28+ and
expressed as percent normalized to pre-infection values. Standard deviations are
indicated by vertical bars. ⁎, p-valueb0.05.
305R. Schulte et al. / Virology 383 (2009) 300–309levels of circulatingCD4+memory T-cells in blood and viral loads in the
acute phase of infection.
When the ﬁrst rAd5 booster immunization was given orally by
spray followed by a systemic application of the same vectors, IFN-γ-
secretion of PBMCs was increased in this group coinciding with a
broader immune response on the day of challenge. Such a response issupposed to be important for reduction of viral load (Hel et al., 2006).
Maybe the inclusion of IL-15 vectors caused this stronger response of
the mucosal group as it has been shown in mice that mucosal applic-
ation of IL-15-expressing vectors enhanced the generation of CD8+
effector T-cells (Toka and Rouse, 2005). In addition, the immunosti-
mulatory peptide is known to activate immature andmature dendritic
cells (Yang et al., 2002) which reside at high numbers in mucosal
tissues. This activationmay have led to an increased immune response
in the mucosal group. Moreover, inclusion of a mucosal vector applic-
ation led to a strong T-cell proliferative response on the day of
challenge which is known to contribute to a favorable long-term
virological outcome (Michelini et al., 2004; Spring et al., 2001). Add-
itionally, this T-cell proliferation signiﬁcantly correlated with neutra-
lizing and binding SIV-antibodies determined on the same day and
2 weeks thereafter. This emphasizes the supportive role of T-cell
proliferation for generating B-cell responses thus probably contribut-
ing to a favorable disease course.
The nAb titers against SIVmac251 reached a plateau following the
ﬁrst systemic rAd5 boosting in the systemic group. By comparison,
mucosal immunization alone did not generate any measurable nAb
titers, possibly due to slow or transient mucosal uptake of the vector
antigen, but the nAbs appeared after systemic boosting. In our study, a
combination of mucosal and systemic immunization secured signiﬁ-
cantly higher SIV-nAb responses compared to a systemic only regimen
as reportedpreviously (Barnett et al., 2008).Moreover, in our vaccinees
reduced levels of acute viremia correlated inversely with the titer of
SIV-nAb at 2 wpc, conﬁrming the necessity to mount this kind of
anamnestic response for early viral containment. Limited analysis of
humoral responses considered to be linked to mucosal compartments
(i.e. IgA in blood) revealed the presence of SIV-speciﬁc IgA in some
animals after ﬁnal immunization and an anamnestic response in all
vaccinees independent of the route of immunization. On the basis of all
of these results we hypothesize that oral rAd5 administration potently
primes for greater and longer lasting subsequent immunological
responses.
The mechanism by which oral immunization followed by intra-
muscular boost with rAd5 vaccine elicited the enhanced T-cell and
antibody responses remains to be elucidated. However, several reports
suggested potential advantages of mucosal vaccination when given
prior to systemic immunization (Ciabattini et al., 2004; Huang et al.,
2007a, 2007b) sincemucosal immunization induces bothmucosal and
systemic immune responses (Makitalo et al., 2004) while intramus-
cular immunization preferentially stimulates systemic responses. In
future experiments, more sophisticatedmethods need to be applied to
analyze for immune responses in different mucosal compartments for
which particularly the vagina and intestine are regarded as theﬁrst site
of defense against HIV/SIV entry (Mattapallil et al., 2005).
306 R. Schulte et al. / Virology 383 (2009) 300–309We have previously reported that the loss of CD4+ T-cells was
delayed in vaccinated macaques able to control acute viremia (Suh et
al., 2006). Additional literature supports the relevance of memory T-
cell preservation on vaccine outcome (Letvin et al., 2006;Mattapallil et
al., 2006). Here we investigated whether preservation of T-cell me-
mory was related to viremia control. Compared to all vaccinees, the
population of TCM signiﬁcantly decreased in control animals at 2 wpc.
In all animals the level of this T-cell subset inversely correlated with
plasma viremia during a period spanning 20 weeks after infection and
also correlated with SIV binding antibodies during acute infection
indicating the impact of the memory T-cell subset on viremia control
and SIV-speciﬁc antibody production. These particularmemory T-cells
have been described previously to be associated with better clinical
outcome (Letvin et al., 2006). We further assessed whether the T-cell
proliferation was associated with preservation of this critical CD4+ T-
cell population. Lymphoproliferative responses on the day of challenge
were positively and signiﬁcantly associated with maintained levels of
CD4+ memory T-cells at peak viremia underlining the importance of
this functional immune response in suppressing pathogenic sequelae
of infection.
It is not clear why despite a stronger systemic T- and B-cell immu-
nity in the mucosal group the level of viremia control was similar in
both vaccine groups. Maybe even ourmucosal vaccine strategy did not
induce immune response at relevant sites like the gut where massive
viral replication occurs early on. In addition to the adaptive responses
determined, other factors such as innate immunity may play a role in
acute viremia control in SIV-infectedmacaques (Giavedoni et al., 2000)
and in the preservation of CD4+memory T-cells. However, activation of
the innate immunity by the vector alone can be ruled out sincewehave
demonstrated earlier that application of Ad5 expressing an SIV-
unrelated gene did not inﬂuence viral load after SIV-challenge (Suh et
al., 2006).
Moreover, we analyzed for NK activity early after challenge by
incubating PBMC with NK-sensitive K562 cells. Despite no statistical
signiﬁcance, a lower activity of NK-cells was observed in the vaccinees
compared to the controls (data not shown) suggesting that the adap-
tive immune response had a more profound effect on viremia control.
Due to the failed human phase IIB STEP vaccine trial there is in-
creasing concern about reduced efﬁcacy of adenoviral vaccine vectors
occasioned by elicitation of anti-adenoviral antibodies (Casimiro et al.,
2005; Sekaly, 2008). Consequently, we determined the presence of
these antibodies during immunization and their inﬂuence on immu-
nization and infection outcome. We conﬁrmed that a single mucosal
rAd5 application alone did not raise any measurable nAbAd5 titers
(Stahl-Hennig et al., 2007a, 2007b). Only after a systemic application
nAb against Ad5 levels rose in both vaccine groups. In general, nAb
against Ad5 are considered to mitigate immune responses against the
incorporated genes. In our case, such vector-speciﬁc immunity might
have inhibited the burst of immune reactions in the systemic group as
the response at week 36 was inversely correlated with lymphocyte
proliferation at week 40 (pb0.05). The increased production of neutra-
lization antibodies to rAd5 (Fig. 3B) most likely interfered with boos-
ting of helper T-cell responses in the systemic group, resulting in
weaker antibody and IFN-γ ELISPOT T-cell responses.
In contrast to the STEP study we used a heterologous prime-boost
regimenwith amore attenuated Ad5. This setting secured a broad CTL-
response (Fig. 2) required for an effective HIV-vaccine (Watkins et al.,
2008). Although the differences in immune responses between the
mucosal and systemic group were not reﬂected in viremia control, the
data clearly show that the combination of mucosal and systemic
immunization provides an alternative avenue to repetitive invasive
procedures characterizing systemic immunization.
Since vaccinated animals controlled acute viremia signiﬁcantly
better than unvaccinated ones independent of the immunization
route, we aimed to assess whether this viremia control was also in-
ﬂuenced by the Mhc-class 1 background. We demonstrated that vac-cination protected from initial high viral loads independent of the test
animals' genetic composition as shown before (Letvin et al., 2006). Our
vaccine-mediated reduction of viral load lasted until 8wpc. Thereafter,
the animals' genetic background signiﬁcantly affected viremia control.
This effect was further corroborated by the inclusion ofMhc-identical
siblings, conﬁrming an attenuation of the vaccine effect during the
post-acute and chronic phases of infection and the dominance ofMhc-
driven inﬂuence on viremia control.
Taken together, our vaccination strategy procured strong SIV Gag-
speciﬁc IFN-γ and T-cell proliferation responses in both vaccine groups
which were independent of Mhc-background. Broader and stronger
SIV-speciﬁc and reduced vector-speciﬁc immune reactions were
induced in the mucosally immunized animals. Despite this increased
immunogenicity there was no signiﬁcant difference in the vaccine
efﬁcacy between the two vaccine arms. Nevertheless, these ﬁndings
strongly argue for the inclusion of mucosal vector administration in
any AIDS-vaccine approach as it is less invasive, easily applicable and
could reduce acceptability issues.
Materials and methods
Animals
Eighteen rhesus macaques of Indian origin, seronegative for SIV,
simian retrovirus and T-cell leukemia virus, were housed at the
German Primate Center under standard conditions according to the
German animal protection law which complies with the European
Union guidelines on the use of non-human primates for biomedical
research. Major histocompatibility complex (Mhc) class I allele geno-
typing of themacaqueswas done as described elsewhere (Muehl et al.,
2002; Sauermann et al., 2008). The animals were assigned to three
experimental groups of six animals each (two vaccine groups and one
control group). We included four Mhc identical siblings which were
positive for both Mamu-A1⁎01 and -B⁎17. Two of those were assigned
to the control group and one each to the vaccine groups. To balance the
number of Mamu-A1⁎01+ animals in the study groups, one additional
Mamu-A1⁎01+ B⁎17- animal was allocated to each of the two vaccine
groups. Every 2 to 4 weeks during immunization and post-challenge
(wpc), blood specimens were collected by venipuncture. Physical
examination, bleeding and immunizations were carried out under
ketamine anesthesia.
Vaccination and challenge
Avaccine regimen comprising DNA priming and rAd5 boostingwas
employed. The DNA regimen included four different pGX10 plasmid
vectors expressing a codon-optimized SIV gag, SIVenvΔtransmem-
brane, SIVnef-tat-vpx-vif-tat or human IL-15 (1.5 mg/construct). Since
Tat-speciﬁc responses have been associated with slow AIDS progres-
sion inHIV-infected humans (van Baalen et al.,1997, Zaguryet al.,1998)
the tat gene was included twice into the construct in order to present
larger amounts of Tat peptides to the immune system. The amount of
Nef-Tat-Vpx-Vif-Tat protein in DNA-transfected cells was veriﬁed by
Western blot using anti-SIV Nef antibodies (ARP4007, NIBSC). It was
comparable to that of Nef protein expressed by transfection of nefDNA
alone, indicating that fusion of the regulatory genes did not affect
expression of the protein. We also included 1 mg of an immunosti-
mulatory peptide (Trp-Lys-Tyr-Met-Val-D-Met; Yang et al., 2002) in
each DNA application. For booster immunizations ﬁve E1/E3 deleted
replication-incompetent rAd5 vectors were used expressing SIV gag,
env or human IL-15 (rAd5-IL-15) as described above and non-codon
optimized vif-nef or tat-vpx as reported (Suh et al., 2006). The rAd5
vectors expressing the different SIV genes are later referred to as rAd5-
SIV. The original SIV envelope transmembrane sequencewas truncated
and the signal sequence of the env gene was replaced by a tissue
plasminogen activator signal sequence in order to enhance secretion of
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phosphate buffer for DNA and Tris buffer for rAd5.
The two vaccine groups received an intramuscular (i.m.) DNA
priming at weeks 0, 8 and 16. After priming, one group was boosted
twice i.m. (systemic group) with escalating doses of rAd5-SIV at weeks
24 (1×108 pfu/construct) and 32 (2×109 pfu/construct)while the other
group received the same boost ﬁrst mucosally (mucosal group) via
oropharyngeal spray (40) (1×109 pfu/construct) and then i.m.
(2×109 pfu/construct) at the respective time points. The control
group received the respective buffers i.m. at the corresponding time
points. Twelve weeks after ﬁnal immunization all animals were
challenged orally with approximately 6000 median tissue culture
infectious doses of SIVmac239 as described elsewhere (Kuate et al.,
2006).
IFN-γ ELISpot and lymphoproliferation assay
IFN-γ ELISpot assaywas performedusing SIVGag (EVA7066, NIBSC,
UK); Env1 (Cat# 6528–6582, NIH, Maryland, USA) and Env2 (Cat#
6583–6637, NIH), Nef (EVA777, NIBSC) and Tat (EVA7069, NIBSC)
peptides as described previously (Suh et al., 2006). In addition, we also
used peptide pools comprising p26 (ARP714.1-22, NIBSC) and vif
(6205, NIH). The IFN-γ positive cells were counted using a Bioreader®-
3000 (Bio-Sys GmbH, Karben, Germany). Individual values obtained by
peptide stimulation minus medium control were normalized to
individual pre-immunization values and consideredpositive if yielding
a difference greater than 100 spot forming cells (SFC) per million
peripheral blood mononuclear cells (PBMC). The arbitrary cut-off was
deﬁned to consider individual assay to assay variations. The results
from separate stimulations with the Env1 and Env2-peptide pools are
presented as the sum of the spot numbers of both pools. A T-cell
proliferation assay was performed in triplicate by stimulating fresh
PBMCswith aldrithiol-2 treated (AT-2) SIV or inactivatedmicrovesicles
derived fromSUP-T1 cells (ﬁnal protein concentration,1 μg/ml) (Spring
et al., 2001). Plateswere read byaβ-plate reader. The stimulation index
(SI) was calculated by dividing the counts per minute (cpm) of the
stimuli tested by the cpm of the medium response for each animal's
sample. A SI above two was considered as a positive response.
FACS analyses of T-cells
Whole blood lymphocytes were stained with a pre-titrated anti-
body mixture comprising anti-CD3-Alexa700 (clone SP34-2), CD4-
Alexa405 (clone SK3), CD8-AmCyan (clone SK1), CD95-APC (clone
DX2), CD28-PerCP-Cy5.5 (clone L293), CD29-FITC (clone 4B4), CD195-
PE (clone 3A9) and CD45RA-ECD (clone 2H4). Stained lymphocytes
were analyzed for the expression of cell surface markers by ﬂow
cytometry on a LSR II ﬂow cytometer (Becton Dickinson, Heidelberg,
Germany). Lymphocyte populations were gated based on forward and
side scatter characteristics and expression of CD3 surface antigen. Data
were acquired with BD FACS Diva 5.1 Software (Becton Dickinson)
before analysis with FlowJo 6.4 Software (TreeStar).
Detection of antibody responses
A standard ELISA to detect antibodies against SIV (Kuate et al.,
2006) was performed on plates coated with 30 ng per well of recom-
binant p27 (EVA643, NIBSC) or recombinant SIVgp130 (EVA670,
NIBSC). For IgG determination test plasma was diluted 1:200 and the
optical densities weremeasured at 450 nm. SIV-speciﬁc IgA antibodies
in serum and from rectal swabs were determined with the following
modiﬁcations. Serum samples were diluted serially without any fur-
ther adjustments in their immunoglobulin concentrations and reacted
with recombinant SIV p27 antigen or gp130 at a concentration of 50 ng
per well each. Upon development of a strong colour in the positive
control, the staining reaction was stopped and the optical density wasmeasured. The titers were expressed as the reciprocal of the highest
dilution yielding optical densities twice above the autologous pre-
immunization values.
Neutralizing antibodies against SIVmac were determined with a
SIVmac251/32H neutralization assay. Except for a few modiﬁcations,
the assay was conducted as previously described (Chackerian et al.,
1995). Brieﬂy, rhesus macaque mammary tumor cells expressing CD4
and β-galactosidase (sMAGI cell-line, NIH #2955) were seeded into a
96-well U-bottomplate at a concentration of 7000 cells/well in DMEM.
An aliquot of SIVmac251/32H generating around 200 infectious foci
was incubated for 1 h at 37 °C with ten 3-fold serial dilutions starting
from 1:12. Respective serum sample/virus mixtures were added to
sMAGI cells and incubated at 37 °C and5%CO2 for 50min before adding
15 μg/ml DEAE dextran. After two days of incubation, plates were ﬁxed
and the infectious foci stained in the presence of X-Gal. The
neutralizing titer was deﬁned as the reciprocal of the ﬁnal sample
dilution giving more than 80% reduction in infectious foci.
The presence of adenovirus-neutralizing antibodies compromises
target-speciﬁc immune responses in vaccine regimens that employ
adenovirus as a vaccine vector (McConnell et al., 2007; Nwanegbo et
al., 2004). Because of this, adenovirus neutralizationwas evaluated in a
green ﬂuorescent foci reduction assay as previously described (Farina
et al., 2001). Brieﬂy, complement-inactivated macaque sera were
tested in 2-fold serial dilutions starting with a 1:10 dilution. One
hundred microliters of diluted sera were added to an equal volume of
rAd5 expressing enhanced green ﬂuorescent protein (EGFP) and incu-
bated at 4 °C for 2 h. After incubation,150 μl of the virus/serummixture
was transferred to corresponding wells of a 96-well ﬂat-bottomed
plate pre-plated with 2×104 of HEK293 cells. After incubation at 37 °C
in 5% CO2 for 48 h, plates were examined under a ﬂuorescent micro-
scope to determine the percentage of cells expressing EGFP. Neutraliz-
ing titers were deﬁned as the reciprocal of the serum sample dilution
giving N50% reduction in the number of EGFP-expressing cells com-
pared to infected controls incubated with autologous pre-immuniza-
tion sera only.
Plasma viral RNA quantitation
Viral RNA was isolated from frozen plasma samples following the
MagAttract Virus Mini M48 protocol (Qiagen, Hilden, Germany). Puri-
ﬁed SIV RNAwas quantiﬁed using TaqMan-based real-time PCR on an
ABI-Prism 7500 sequence detection system (Applied Biosystems) as
described (Negri et al., 2004). Ampliﬁed viral RNA was expressed as
SIV-RNA copies per milliliter plasma.
Statistics
Data on the number of RNA copies, ELISA titers, proliferation assays,
neutralization titers, survival time and T-cells were analyzed with
GraphPad Prismversion 4 (GraphPad Software). Comparisons between
groups were performed with the nonparametric two tailed Mann–
Whitney's U test. Associations between parameters were analyzed
with two tailed Pearson's correlation. Differences and associations
between groupswere considered signiﬁcant at p-values less than 0.05.
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